(A19_069_2015_0690081_71) INNOVATIVE VIRUS VACCINE ASSESSMENT TESTS (Q2065724)
Jump to navigation
Jump to search
Project Q2065724 in Italy
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | (A19_069_2015_0690081_71) INNOVATIVE VIRUS VACCINE ASSESSMENT TESTS |
Project Q2065724 in Italy |
Statements
39,058.86 Euro
0 references
78,117.71 Euro
0 references
50.0 percent
0 references
29 May 2015
0 references
25 January 2018
0 references
29 May 2018
0 references
VISMEDERI SRL
0 references
43°46'11.53"N, 11°15'20.09"E
0 references
L?INFLUENZA ? UNA PRIORIT? ASSOLUTA NEL CAMPO DELLA SALUTE PUBBLICA PER IL SUO IMPATTO SUL BENESSERE GLOBALE E LA MINACCIA DI EVENTI PANDEMICI. I TEST SIEROLOGICI ATTUALMENTE IN USO, UTILIZZATI PER LE LICENZE DEI VACCINI ANTI-INFLUENZALI, SONO ORMAI DATATI E STANNO DIVENTANDO DESUETI ED INSODDISFACENTI. GLI ENTI REGOLATORI COME FDA (FOOD AND DRUG AMMINISTRATION), EMA (EUROPEAN MEDICINES AGENCY) E PMDA (PHARMACEUTICALS AND MEDICAL DEVICES AGENCY) HANNO SOTTOLINEATO LA NECESSIT? DI INTRODURRE TEST INNOVATIVI PER LA VALUTAZIONE DEI VACCINI ANTI-INFLUENZALI. IL TEST DI MICRO NEUTRALIZZAZIONE (MN), PER ESEGUIRE IL QUALE SI USA IL VIRUS VIVO, ? UN ESEMPIO DI TEST INNOVATIVO. IL LIMITE DI QUESTO TEST DI ANALISI ? LA NECESSIT? DI UTILIZZARE IL VIRUS VIVO, CON CONSEGUENTE RISCHIO PER GLI OPERATORI E NECESSIT? DI LABORATORI AD ALTO CONTENIMENTO. IL PROGETTO INNOVIRAL ? FOCALIZZATO SULLO SVILUPPO E CONVALIDA DI UN NUOVO SAGGIO INNOVATIVO PER LA VALUTAZIONE DELL?IMMUNOGENICIT? DEI VACCINI INFLUENZ (Italian)
0 references
L?????????????? A PRIOR T? IN THE FIELD OF PUBLIC HEALTH ABSOLUTE DUE TO ITS IMPACT ON GLOBAL WELFARE AND THE THREAT OF PANDEMIC EVENTS. THE CURRENT SEROLOGICAL TESTS USED FOR THE LICENCES OF ANTI-INFLUENZALI VACCINE LICENCES ARE NOW DATED AND ARE BECOMING BLEAK AND UNSATISFACTORY. HAVE REGULATORS RECOGNISED AS FDA (FOOD AND DRUG ADMINISTRATION), EMA (EUROPEAN MEDICINES AGENCY) AND PMDA (PHARMACEUTICALS AND MEDICAL DEVICES AGENCY) HAVE HIGHLIGHTED THE NEED? TO INTRODUCE INNOVATIVE TESTS FOR THE EVALUATION OF THE ANTI-INFLUENZALI VACCINES. THE MICRONEUTRALISATION TEST (MN) FOR USING THE LIVE VIRUS? AN EXAMPLE OF AN INNOVATIVE TEST. DOES THIS TEST LIMIT? WHAT IS NECESSARY? USING THE LIVE VIRUS, WHICH POSES A RISK TO OPERATORS AND NECESSARY? HIGH CONTAINMENT LABORATORIES. DOES THE INNOVIRAL PROJECT? FOCUS ON THE DEVELOPMENT AND VALIDATION OF A NEW INNOVATIVE TEST FOR THE EVALUATION OF THE IMMUNGAENIT? OF VACCINES AFFECTED (English)
0 references
LA GRIPPE? UN ORDRE DE PRIORITÉ? ABSOLUE DANS LE DOMAINE DE LA SANTÉ PUBLIQUE POUR SON IMPACT SUR LE BIEN-ÊTRE MONDIAL ET LA MENACE D’ÉVÉNEMENTS PANDÉMIQUES. LES TESTS SÉROLOGIQUES ACTUELLEMENT UTILISÉS POUR L’HOMOLOGATION DES VACCINS ANTIGRIPPAUX SONT MAINTENANT DÉPASSÉS ET DEVIENNENT OBSOLÈTES ET INSATISFAISANTS. LES ORGANISMES DE RÉGLEMENTATION TELS QUE LA FDA (ADMINISTRATION DES ALIMENTS ET DES MÉDICAMENTS), L’EMA (AGENCE EUROPÉENNE DES MÉDICAMENTS) ET LE PMDA (AGENCE DES PRODUITS PHARMACEUTIQUES ET DES DISPOSITIFS MÉDICAUX) ONT-ILS INSISTÉ SUR LA NÉCESSITÉ? INTRODUIRE DES TESTS NOVATEURS POUR L’ÉVALUATION DES VACCINS ANTIGRIPPAUX. LE TEST DE MICRONEUTRALISATION (MN), POUR EFFECTUER LEQUEL LE VIRUS VIVANT EST UTILISÉ? UN EXEMPLE DE TEST INNOVANT. LA LIMITE DE CE TEST? TU EN AS BESOIN? UTILISER LE VIRUS VIVANT, CE QUI ENTRAÎNE UN RISQUE POUR LES OPÉRATEURS ET LES BESOINS? LABORATOIRES DE CONFINEMENT ÉLEVÉS. LE PROJET INNOVIRAL? AXÉ SUR L’ÉLABORATION ET LA VALIDATION D’UN NOUVEL ESSAI NOVATEUR POUR L’ÉVALUATION DE?IMMUNOGENICIT? DES VACCINS INFLUENZ (French)
16 December 2021
0 references
Identifiers
D52C15000430009
0 references